Opinions expressed by Digital Journal contributors are their own.
We now live in a world where scientists can edit genes, and scientific advancements can rid the world of disease, making the value chain of CRISPR QC paramount. Unlike researchers treating patients directly or scientists sequencing human DNA, CRISPR QC is the wise mother who is their safeguard, offering preventative measures to ensure the safe and reliable application of this revolutionary technology.
CRISPR QC’s technology combines two Nobel Prize-winning innovations: graphene and CRISPR. Graphene, a nanomaterial discovered by Andre Geim and Konstantin, forms the core of the wire sensor. CRISPR, created by Jennifer Doudna and Emmanuelle Charpentier, is a revolutionary gene-editing tool that allows scientists to make precise changes to an organism’s DNA. It acts like molecular scissors, enabling the removal, addition, or modification of specific sections of genetic material.
The gene editing landscape is relatively new in “science” terms. But, it has become much more accessible, and gene editing techniques and technologies are becoming easier to use. Next-gen sequencing has also made it affordable to sequence genomes, but comprehending how the genomes truly function remains uncertain.
One of the critical contributions of CRISPR QC is to add clarity. Different ethnic backgrounds exhibit variations in genomic makeup and drug responses, creating uncertainties and risk in patient outcomes. CRISPR QC addresses this by quantifying risks and providing consistent performance, fostering greater understanding in the evolving field.
CRISPR QC’s CEO, Ross Bundy, emphasizes this point, “That’s where we come in. That’s a lot of the work we’re doing… We’ve gotten in very early with the National Institute of Standards and Technology. We can show a consistent performance and at least minimize many of the risk factors.”
CRISPR QC’s most significant value to its customers may be the insights and contextual analysis the technology provides, which bridges deep scientific knowledge and customer value. Unlike their competition, CRISPR QC’s sensor technology provides timely and progressive measurements.
Bundy explains, “Our measurement is very forward-looking. We can do this because it’s on a chip. It’s very fast. It’s a couple of hours, whereas most other methods take months. And, more importantly, once you start putting together how the numbers work out of our system to correlate to the cell that they want to edit, to correlate to those good results that they want to edit, you can start looking at its performance metric. … I can look at every step in the process, and we enable our customers to understand where they got good and bad results in their steps. That’s the conversations we have with customers. We’re helping them understand their science better, and that type of measurement doesn’t currently exist in the field.”
Other companies offer a retrospective analysis but don’t offer predictive data or insights to improve outcomes before cell work. The importance of this real-time data interpretation and the provision of actionable insights provided by CRISPR QC’s Analytics Platform is revolutionary. It provides detailed insights into various CRISPR elements that are essential, and its one-of-a-kind machine learning-powered algorithm provides actionable insights which saves time and effort in bringing labs’ products to market.
More exciting discoveries in the world of gene editing are in the future. CRISPR QC’s breakthroughs are critical to those discoveries coming to fruition. Their CRISPR Analytics Platform quantifies risks, ensures consistency, and offers valuable insights — empowering researchers and scientists to change the world.
Find out more about CRISPR QC.
